脳性副腎白質ジストロフィー（CALD）の世界市場レポート 2025年

脳性副腎白質ジストロフィー（CALD）市場規模は、今後数年で急成長が見込まれます。2029年には130億5,000万米ドルに成長し、CAGRは14.6%となります。予測期間における成長の原動力は、遺伝子治療ソリューションの出現、新生児スクリーニング技術の拡大、標的ドラッグデリバリーシステムの開発、希少疾患研究への投資の増加、デジタルヘルスツールの導入拡大、個別化治療への需要の高まり、バイオテクノロジー企業と製薬企業の提携、世界のアドボカシーキャンペーンによる認知度の向上などです。主な動向としては、CRISPRによる遺伝子編集、AIを活用した診断アルゴリズム、高度な神経画像技術、次世代シーケンサーの進歩、脳を標的としたナノ医療、神経モニタリング用ウェアラブルデバイス、治療計画用デジタルツインシミュレーション、クラウドベースのゲノムデータ共有、介護者トレーニング用バーチャルリアリティ、安全な患者データ管理用ブロックチェーンなどが挙げられます。

ヘルスケア支出の増加が脳性副腎白質ジストロフィー（CALD）市場の成長を牽引すると予想されます。ヘルスケア支出は、高齢化、慢性疾患の蔓延、治療法の進歩、薬剤費の高騰、医療保険の拡大などにより増加の一途をたどっています。ヘルスケア資金の増加は、診断ツールの開発、遺伝子治療や幹細胞移植などの革新的治療、CALDに対する専門的治療や早期介入への患者アクセスの改善を支えています。例えば、2024年12月、米国の連邦政府機関であるメディケア・メディケイド・サービスセンター（CMS）は、2023年の国民医療費（NHE）が7.5％増加し、国内総生産（GDP）の成長率6.1％を上回ったと報告しました。2023年から2032年までの今後10年間で、NHEは年平均5.6％成長し、GDPに占めるヘルスケア支出の割合は2022年の17.3％から2032年には19.7％に増加すると予測されています。この継続的なヘルスケア支出の増加が、CALD市場の拡大を牽引しています。

脳性副腎白質ジストロフィー（CALD）市場の各社は、医学的ブレークスルーを推進し、遺伝子治療などの革新的な治療法を開発するための規制当局の承認に注力しており、病気の進行を食い止め、患者の予後を改善し、この希少で生命を脅かす障害に根治的な治療を提供する可能性があります。遺伝子治療では、患者の細胞内の欠陥遺伝子を修正または置換することで、疾患の治療や治癒を目指します。例えば、2022年9月、米国のバイオテクノロジー企業であるBluebird Bio Inc.は、早期から活動的な脳性副腎白質ジストロフィー（CALD）を持つ4～17歳の男児の神経機能障害の進行を遅らせるSkysona（elivaldogene autotemcel）について、米国食品医薬品局（FDA）から早期承認を取得しました。スカイソナは、レンチウイルスベクター（LVV）を用いた生体外導入により、ABCD1遺伝子の機能的コピーを患者の造血幹細胞（HSC）に導入する1回限りの遺伝子治療薬です。この新たに導入された遺伝子は、超長鎖脂肪酸（VLCFA）の分解を助けるALDタンパク質（ALDP）の産生を可能にし、炎症と脱髄の進行を遅らせたり予防したりする可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界脳性副腎白質ジストロフィー（CALD） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脳性副腎白質ジストロフィー（CALD）市場：成長率分析
• 世界の脳性副腎白質ジストロフィー（CALD）市場の実績：規模と成長, 2019-2024
• 世界の脳性副腎白質ジストロフィー（CALD）市場の予測：規模と成長, 2024-2029, 2034F
• 世界脳性副腎白質ジストロフィー（CALD）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脳性副腎白質ジストロフィー（CALD）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食事管理
• 医薬品
• 幹細胞療法
• 世界の脳性副腎白質ジストロフィー（CALD）市場患者の年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大人
• 子供たち
• 乳児
• 十代の若者たち
• 世界の脳性副腎白質ジストロフィー（CALD）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘルスケア施設
• 患者と介護者
• 製薬会社
• 世界の脳性副腎白質ジストロフィー（CALD）市場、食事管理の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロレンツォのオイル
• オメガ3脂肪酸
• 脂肪酸サプリメント
• 世界の脳性副腎白質ジストロフィー（CALD）市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 抗酸化物質
• 抗炎症薬
• 世界の脳性副腎白質ジストロフィー（CALD）市場幹細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血幹細胞移植（HSCT）
• 遺伝子治療

第7章 地域別・国別分析

• 世界の脳性副腎白質ジストロフィー（CALD）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の脳性副腎白質ジストロフィー（CALD）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脳性副腎白質ジストロフィー（CALD）市場：競合情勢
• 脳性副腎白質ジストロフィー（CALD）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Vertex Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Poxel S.A.
• Neuraxpharm Group
• Viking Therapeutics Inc.
• MedDay Pharmaceuticals SAS
• Calico Life Sciences
• Magenta Therapeutics Inc.
• SOM Biotech
• Minoryx Therapeutics S.L.
• NeuroVia Inc.
• SwanBio Therapeutics Inc.
• Autobahn Therapeutics Inc.
• Bluebird Bio Inc.
• Orpheris Inc.
• Sperogenix Therapeutics
• Abliva

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脳性副腎白質ジストロフィー（CALD）市場2029：新たな機会を提供する国
• 脳性副腎白質ジストロフィー（CALD）市場2029：新たな機会を提供するセグメント
• 脳性副腎白質ジストロフィー（CALD）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cerebral adrenoleukodystrophy (CALD) is a rare, progressive neurological disorder primarily affecting males, caused by mutations in the **ABCD1** gene. It is characterized by the accumulation of very long-chain fatty acids in the brain, leading to the destruction of myelin, the protective covering of nerve cells. CALD is a form of adrenoleukodystrophy (ALD) that affects the brain and spinal cord, resulting in symptoms such as cognitive decline, behavioral changes, and motor dysfunction.

The primary treatment approaches for CALD include dietary management, medications, and stem cell therapy. Dietary management focuses on modifying the patient's diet to help control symptoms. The condition affects various patient age groups, including adults, children, infants, and teens, while key end users include healthcare facilities, patients and caregivers, and pharmaceutical companies.

The cerebral adrenoleukodystrophy market research report is one of a series of new reports from The Business Research Company that provides cerebral adrenoleukodystrophy market statistics, including cerebral adrenoleukodystrophy industry global market size, regional shares, competitors with an cerebral adrenoleukodystrophy market share, detailed cerebral adrenoleukodystrophy market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral adrenoleukodystrophy industry. This cerebral adrenoleukodystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cerebral adrenoleukodystrophy (CALD) market size has grown rapidly in recent years. It will grow from $6.58 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth during the historic period can be attributed to increased awareness of rare diseases, the expansion of newborn screening programs, a growing focus on neurodegenerative disorders, the introduction of Lorenzo's oil, advancements in research on peroxisomal disorders, advocacy by patient support groups, and improvements in healthcare infrastructure.

The cerebral adrenoleukodystrophy (CALD) market size is expected to see rapid growth in the next few years. It will grow to $13.05 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The projected growth in the forecast period is driven by the emergence of gene therapy solutions, the expansion of newborn screening technologies, the development of targeted drug delivery systems, increasing investment in rare disease research, the rising adoption of digital health tools, a growing demand for personalized treatments, collaborations between biotech and pharmaceutical companies, and enhanced awareness through global advocacy campaigns. Key trends include gene editing with CRISPR, AI-powered diagnostic algorithms, advanced neuroimaging techniques, next-generation sequencing advancements, brain-targeted nanomedicine, wearable devices for neurological monitoring, digital twin simulations for treatment planning, cloud-based genomic data sharing, virtual reality for caregiver training, and blockchain for secure patient data management.

The increase in healthcare spending is expected to drive the growth of the cerebral adrenoleukodystrophy (CALD) market. Healthcare expenditures continue to rise due to aging populations, the prevalence of chronic diseases, advancements in medical treatments, rising drug costs, and expanded health coverage. Increased healthcare funding supports the development of diagnostic tools, innovative treatments such as gene therapy and stem cell transplantation, and improved patient access to specialized care and early intervention for CALD. For example, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a US-based federal agency, reported that national health expenditures (NHE) grew by 7.5% in 2023, surpassing the gross domestic product (GDP) growth rate of 6.1%. Over the next decade, from 2023 to 2032, NHE is projected to grow at an average annual rate of 5.6%, increasing healthcare spending as a share of GDP from 17.3% in 2022 to 19.7% in 2032. This continued increase in healthcare spending is driving the expansion of the CALD market.

Companies in the cerebral adrenoleukodystrophy (CALD) market are focusing on regulatory approvals to drive medical breakthroughs and develop innovative therapies, such as gene therapies, to halt disease progression, improve patient outcomes, and potentially provide curative treatments for this rare and life-threatening disorder. Gene therapy involves modifying or replacing faulty genes within a patient's cells to treat or cure diseases. For example, in September 2022, Bluebird Bio Inc., a US-based biotechnology company, received accelerated approval from the United States Food and Drug Administration (FDA) for Skysona (elivaldogene autotemcel) to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active cerebral adrenoleukodystrophy (CALD). Skysona is a one-time gene therapy that employs ex vivo transduction with the Lenti-D lentiviral vector (LVV) to introduce functional copies of the ABCD1 gene into a patient's hematopoietic stem cells (HSCs). This newly introduced gene enables the production of the ALD protein (ALDP), which aids in breaking down very long-chain fatty acids (VLCFAs), potentially slowing or preventing further inflammation and demyelination.

In November 2022, Minoryx Therapeutics, a Spain-based biotechnology company, partnered with Neuraxpharm Group under a license agreement for the commercialization of leriglitazone in Europe. Under the agreement, Minoryx granted Neuraxpharm exclusive European rights to leriglitazone, which is currently under review by the European Medicines Agency (EMA) for the treatment of X-linked adrenoleukodystrophy (X-ALD). Neuraxpharm Group, a Germany-based pharmaceutical company, specializes in treating central nervous system (CNS) disorders, including cerebral adrenoleukodystrophy, expanding treatment options for patients across Europe.

Major players in the cerebral adrenoleukodystrophy (cald) market are Pfizer Inc., Sanofi S.A., Novartis AG, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Poxel S.A., Neuraxpharm Group, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Calico Life Sciences, Magenta Therapeutics Inc., SOM Biotech, Minoryx Therapeutics S.L., NeuroVia Inc., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., Bluebird Bio Inc., Orpheris Inc., Sperogenix Therapeutics, Abliva.

North America was the largest region in the cerebral adrenoleukodystrophy (CALD) market in 2024. The regions covered in cerebral adrenoleukodystrophy (CALD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cerebral adrenoleukodystrophy (CALD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cerebral adrenoleukodystrophy (CALD) market consists of revenues earned by entities by providing services such as genetic testing, diagnostic imaging, medical consultations, hematopoietic stem cell transplantation, patient monitoring, counseling and long-term care management for individuals affected by cerebral adrenoleukodystrophy (CALD). The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral adrenoleukodystrophy (CALD) market also includes sales of gene therapies, corticosteroids and supportive care treatments aimed at managing symptoms and slowing disease progression. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cerebral Adrenoleukodystrophy (CALD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cerebral adrenoleukodystrophy (cald) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cerebral adrenoleukodystrophy (cald) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cerebral adrenoleukodystrophy (cald) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Treatment: Dietary Management; Medications; Stem Cell Therapy
• 2) By Patient Age Group: Adults; Children; Infants; Teens
• 3) By End User: Healthcare Facilities; Patients And Caregivers; Pharmaceutical Companies
• Subsegments:
• 1) By Dietary Management: Lorenzo's Oil; Omega-3 Fatty Acids; Fatty Acid Supplements
• 2) By Medications: Corticosteroids; Antioxidants; Anti-inflammatory Drugs
• 3) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT); Gene Therapy
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; Regeneron Pharmaceuticals; Vertex Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cerebral Adrenoleukodystrophy (CALD) Market Characteristics

3. Cerebral Adrenoleukodystrophy (CALD) Market Trends And Strategies

4. Cerebral Adrenoleukodystrophy (CALD) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cerebral Adrenoleukodystrophy (CALD) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cerebral Adrenoleukodystrophy (CALD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cerebral Adrenoleukodystrophy (CALD) Market Growth Rate Analysis
• 5.4. Global Cerebral Adrenoleukodystrophy (CALD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cerebral Adrenoleukodystrophy (CALD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cerebral Adrenoleukodystrophy (CALD) Total Addressable Market (TAM)

6. Cerebral Adrenoleukodystrophy (CALD) Market Segmentation

• 6.1. Global Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Management
• Medications
• Stem Cell Therapy
• 6.2. Global Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Children
• Infants
• Teens
• 6.3. Global Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Healthcare Facilities
• Patients And Caregivers
• Pharmaceutical Companies
• 6.4. Global Cerebral Adrenoleukodystrophy (CALD) Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lorenzo's Oil
• Omega-3 Fatty Acids
• Fatty Acid Supplements
• 6.5. Global Cerebral Adrenoleukodystrophy (CALD) Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Antioxidants
• Anti-inflammatory Drugs
• 6.6. Global Cerebral Adrenoleukodystrophy (CALD) Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation (HSCT)
• Gene Therapy

7. Cerebral Adrenoleukodystrophy (CALD) Market Regional And Country Analysis

• 7.1. Global Cerebral Adrenoleukodystrophy (CALD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cerebral Adrenoleukodystrophy (CALD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cerebral Adrenoleukodystrophy (CALD) Market

• 8.1. Asia-Pacific Cerebral Adrenoleukodystrophy (CALD) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cerebral Adrenoleukodystrophy (CALD) Market

• 9.1. China Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 9.2. China Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cerebral Adrenoleukodystrophy (CALD) Market

• 10.1. India Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cerebral Adrenoleukodystrophy (CALD) Market

• 11.1. Japan Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 11.2. Japan Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cerebral Adrenoleukodystrophy (CALD) Market

• 12.1. Australia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cerebral Adrenoleukodystrophy (CALD) Market

• 13.1. Indonesia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cerebral Adrenoleukodystrophy (CALD) Market

• 14.1. South Korea Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 14.2. South Korea Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cerebral Adrenoleukodystrophy (CALD) Market

• 15.1. Western Europe Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 15.2. Western Europe Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cerebral Adrenoleukodystrophy (CALD) Market

• 16.1. UK Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cerebral Adrenoleukodystrophy (CALD) Market

• 17.1. Germany Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cerebral Adrenoleukodystrophy (CALD) Market

• 18.1. France Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cerebral Adrenoleukodystrophy (CALD) Market

• 19.1. Italy Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cerebral Adrenoleukodystrophy (CALD) Market

• 20.1. Spain Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cerebral Adrenoleukodystrophy (CALD) Market

• 21.1. Eastern Europe Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 21.2. Eastern Europe Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cerebral Adrenoleukodystrophy (CALD) Market

• 22.1. Russia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cerebral Adrenoleukodystrophy (CALD) Market

• 23.1. North America Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 23.2. North America Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cerebral Adrenoleukodystrophy (CALD) Market

• 24.1. USA Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 24.2. USA Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cerebral Adrenoleukodystrophy (CALD) Market

• 25.1. Canada Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 25.2. Canada Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cerebral Adrenoleukodystrophy (CALD) Market

• 26.1. South America Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 26.2. South America Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cerebral Adrenoleukodystrophy (CALD) Market

• 27.1. Brazil Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cerebral Adrenoleukodystrophy (CALD) Market

• 28.1. Middle East Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 28.2. Middle East Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cerebral Adrenoleukodystrophy (CALD) Market

• 29.1. Africa Cerebral Adrenoleukodystrophy (CALD) Market Overview
• 29.2. Africa Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cerebral Adrenoleukodystrophy (CALD) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cerebral Adrenoleukodystrophy (CALD) Market Competitive Landscape And Company Profiles

• 30.1. Cerebral Adrenoleukodystrophy (CALD) Market Competitive Landscape
• 30.2. Cerebral Adrenoleukodystrophy (CALD) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Regeneron Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Vertex Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

31. Cerebral Adrenoleukodystrophy (CALD) Market Other Major And Innovative Companies

• 31.1. Poxel S.A.
• 31.2. Neuraxpharm Group
• 31.3. Viking Therapeutics Inc.
• 31.4. MedDay Pharmaceuticals SAS
• 31.5. Calico Life Sciences
• 31.6. Magenta Therapeutics Inc.
• 31.7. SOM Biotech
• 31.8. Minoryx Therapeutics S.L.
• 31.9. NeuroVia Inc.
• 31.10. SwanBio Therapeutics Inc.
• 31.11. Autobahn Therapeutics Inc.
• 31.12. Bluebird Bio Inc.
• 31.13. Orpheris Inc.
• 31.14. Sperogenix Therapeutics
• 31.15. Abliva

32. Global Cerebral Adrenoleukodystrophy (CALD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cerebral Adrenoleukodystrophy (CALD) Market

34. Recent Developments In The Cerebral Adrenoleukodystrophy (CALD) Market

35. Cerebral Adrenoleukodystrophy (CALD) Market High Potential Countries, Segments and Strategies

• 35.1 Cerebral Adrenoleukodystrophy (CALD) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cerebral Adrenoleukodystrophy (CALD) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cerebral Adrenoleukodystrophy (CALD) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer